Department of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Hematology, The First People Hospital in Yunnan Province, Kunming, China.
BMC Cancer. 2018 Jul 23;18(1):755. doi: 10.1186/s12885-018-4670-5.
This meta-analysis was performed to explore the impact of minimal residual disease (MRD) prior to transplantation on the prognosis for patients with acute lymphoblastic leukemia (ALL).
A systematic search of PubMed, Embase, and the Cochrane Library was conducted for relevant studies from database inception to March 2016. A total of 21 studies were included.
Patients with positive MRD prior to allogeneic stem cell transplantation (allo-SCT) had a significantly higher rate of relapse compared with those with negative MRD (HR = 3.26; P < 0.05). Pre-transplantation positive MRD was a significant negative predictor of relapse-free survival (RFS) (HR = 2.53; P < 0.05), event-free survival (EFS) (HR = 4.77; P < 0.05), and overall survival (OS) (HR = 1.98; P < 0.05). However, positive MRD prior to transplantation was not associated with a higher rate of nonrelapse mortality.
Positive MRD before allo-SCT was a predictor of poor prognosis after transplantation in ALL.
Not applicable.
本荟萃分析旨在探讨移植前微小残留病（MRD）对急性淋巴细胞白血病（ALL）患者预后的影响。
从数据库建立到 2016 年 3 月，我们对 PubMed、Embase 和 Cochrane Library 进行了系统检索，以查找相关研究。共纳入 21 项研究。
与 MRD 阴性患者相比，allo-SCT 前 MRD 阳性患者的复发率显著更高（HR=3.26；P<0.05）。移植前阳性 MRD 是无复发生存（RFS）（HR=2.53；P<0.05）、无事件生存（EFS）（HR=4.77；P<0.05）和总生存（OS）（HR=1.98；P<0.05）的显著负预测因子。然而，移植前阳性 MRD 与较高的非复发死亡率无关。
allo-SCT 前阳性 MRD 是 ALL 移植后不良预后的预测因子。
不适用。
